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Reply
We thank Drs. Li and Zhao for their interest in our paper
(1). They are correct that indirect comparisons cannot address all
the heterogeneity between trials, as well as the underlying patho-
genic mechanisms that they allude to. However, it is not very likely
that there would be major differences in stroke subtypes among the
3 studies. Also, the inclusion and exclusion criteria are broadly the
same in the 3 trials, except for the ROCKET-AF (Rivaroxaban
Once Daily Oral Direct Factor Xa Inhibition Compared With
Vitamin K Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation) trial, wherein more patients may
possibly have a different stroke type than thromboembolism-
related, because of the higher-risk profile.
The only way to definitively address this issue would be to
perform a large head-to-head randomized trial, and with the
current agents, this would need to be a 4-arm noninferiority
randomized trial of dabigatran (2 doses), apixaban, and rivaroxa-
ban, which would probably require a massive number of atrial
fibrillation patients (probably 50,000) and require 5 years of
follow-up.
In the absence of head-to-head comparisons, indirect compar-
isons allow the opportunity to have some insight into how these
novel anticoagulants would perform against each other for the
main efficacy and safety endpoints (2). To that end, our analysis (1)
concludes that there are no profound differences in the major
efficacy and safety endpoints between the novel oral anticoagulants.
This is consistent with other recent papers on the same topic (3,4),
although 1 analysis by Kansal et al. (5) did highlight some
differences with fewer incidents of ischaemic stroke and intracra-
nial hemorrhage, as well as cost effectiveness, when dabigatran was
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Not All Fat Is Equal
We read with interest the paper by Gupta et al. (1). Adipose tissue
is a major source of hormones and cytokines implicated in systemic
inflammatory reactions, metabolic abnormalities, hypertension,
and insulin resistance (2,3). The investigators use body mass index
(BMI) to classify adiposity status. However, it is useful to
re-evaluate how body fat is determined. Numerous studies have
produced evidence that BMI has limited ability to accurately
predict body composition.
So how fat is fat? BMI is the most commonly used measure to
determine adiposity status in everyday clinical practice. It is a safe,
convenient, and popular method. However, the index is an indirect
surrogate of body fat, which is not able to distinguish lean body
mass from fat mass. There is growing body of evidence that BMI
may misclassify weight status in many patients (4–6). It tends to
overestimate normal weight and underestimate overweight or
obesity.
Dual-energy X-ray (DXA) absorptiometry is considered by
many to be a gold standard for assessing body composition (direct
measurement of total body fat and lean soft tissue mass). It
provides a more accurate indication of body fat percentage, which
is one of the fundamental links between obesity and its associated
disease risk.
RR
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February 5, 2013:594–7There are reports that those with elevated body fat percentage
are at increased risk of developing cardiometabolic disease despite
having a normal BMI (7).
When using BMI to determine adiposity status of our patients
in clinical practice, it is important to keep in mind the possibility
of misclassification that may lead to withholding or overusing
preventive or therapeutic interventions.
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Reply
We concur with Dr. Hudzik and colleagues that BMI is an
imprecise measure of adiposity compared with reference measuressuch as DXA (1), and importantly, women generally have more
body fat than men for the same BMI value (2). Accordingly, we
repeated our analyses using sex-specific tertiles of body fat per-
centage measured by DXA rather than BMI categories and found
essentially the same findings. In men, increasing C-reactive protein
(CRP) category (1, 1 to 3, 3 mg/l) was associated with
increased prevalence of coronary artery calcium (CAC) in those in
the first tertile of body fat percentage (p  0.0001), but there was
no association between CRP and CAC in those in the third tertile
(p  0.6) (p interaction CRP  body fat percentage  0.01).
Similar findings were observed in women using body fat percent-
age as a measurement (p interaction CRP body fat percentage
0.02). In our current study, we also demonstrated that the
association between CRP and atherosclerosis differed by waist
circumference category, a third measure of adiposity.
We have previously demonstrated that CRP levels are substan-
tially higher with either increased BMI (3) or body fat percentage
(4); thus, the CRP signal from increased adiposity as reflected in
these measures may overestimate the true atherosclerotic risk in
obese subjects. Although DXA quantification of body fat may be
a more precise adiposity measure than BMI, the potential limita-
tions of CRP measurement in obese subjects appear consistent,
regardless of which measure is used.
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